Anticipated to improve glycemic control (via incretin release) and reduce NAFLD activity (less steatosis, inflammation, and fibrosis) based on animal models. Human trials are in early phases; efficacy in T2D/NAFLD remains to be confirmed. The gene discussed is GCG; the disease is steatosis.